Royalty Pharma

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of therapies for cancer treatment. The company's lead candidate, entinostat, is a class I HDAC inhibitor currently in Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, Syndax is advancing SNDX-5613, a selective inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for acute myeloid leukemia with specific mutations. The company also explores entinostat in combination with immunotherapies such as Keytruda and Tecentriq for various cancers, including non-small cell lung cancer and metastatic breast cancer. Furthermore, Syndax is developing axatilimab, a monoclonal antibody targeting the CSF-1 receptor, currently in trials for chronic graft-versus-host disease. The company maintains collaborative relationships with several major pharmaceutical entities and research organizations to enhance its drug development efforts. Founded in 2005, Syndax Pharmaceuticals is committed to advancing innovative treatments for patients with challenging malignancies.

Ascendis Pharma is a biopharmaceutical company that uses its TransCon prodrug technology platform to create long-acting therapies across endocrinology and oncology. The company's TransCon growth hormone targets growth hormone deficiency in children and has completed Phase III development; TransCon PTH is in Phase II for hypoparathyroidism, and TransCon CNP is in Phase II for achondroplasia; it is pursuing preclinical oncology programs and evaluating systemic and localized delivery; the platform enables control of exposure via TransCon carrier and linker to determine dosing frequency, with prodrugs releasing the active drug in its native form. Ascendis collaborates with Sanofi to co-develop TransCon technologies for diabetes. The company was founded in 2006 and is headquartered in Hellerup, Denmark.

Founded in Boston in 2016, Elektrofi is a preclinical-stage company focused on revolutionizing drug delivery. Its proprietary formulation system can efficiently process a wide range of therapeutic molecules, including large and complex proteins like monoclonal antibodies.

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors to treat diseases where muscle performance is compromised. The company develops small-molecule medicines designed to increase muscle function and contractility and pursues muscle-directed investigational therapies for conditions such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy and chronic obstructive pulmonary disease.

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors to treat diseases where muscle performance is compromised. The company develops small-molecule medicines designed to increase muscle function and contractility and pursues muscle-directed investigational therapies for conditions such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy and chronic obstructive pulmonary disease.

Teva Pharmaceuticals is a global leader in the pharmaceutical industry, specializing in the development, production, and marketing of both generic and proprietary branded medications, as well as active pharmaceutical ingredients. The company is known for its extensive portfolio of high-quality generic medicines, which are supported by innovative research and a complex supply chain. Teva's commitment to improving patient health is reflected in its growing range of specialty and biopharmaceutical products, aimed at addressing a variety of medical needs worldwide.

Ascendis Pharma is a biopharmaceutical company that uses its TransCon prodrug technology platform to create long-acting therapies across endocrinology and oncology. The company's TransCon growth hormone targets growth hormone deficiency in children and has completed Phase III development; TransCon PTH is in Phase II for hypoparathyroidism, and TransCon CNP is in Phase II for achondroplasia; it is pursuing preclinical oncology programs and evaluating systemic and localized delivery; the platform enables control of exposure via TransCon carrier and linker to determine dosing frequency, with prodrugs releasing the active drug in its native form. Ascendis collaborates with Sanofi to co-develop TransCon technologies for diabetes. The company was founded in 2006 and is headquartered in Hellerup, Denmark.

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors to treat diseases where muscle performance is compromised. The company develops small-molecule medicines designed to increase muscle function and contractility and pursues muscle-directed investigational therapies for conditions such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy and chronic obstructive pulmonary disease.

Blueprint Medicines is a Cambridge, Massachusetts-based biopharmaceutical company that develops targeted, small-molecule therapies to treat genomically defined cancers, rare diseases, and related conditions. The company focuses on precision medicines that address molecular drivers and resistance mechanisms, advancing a pipeline that includes avapritinib for systemic mastocytosis and certain gastrointestinal stromal tumors, BLU-263, a KIT inhibitor for indolent systemic mastocytosis and other mast cell disorders, fisogatinib for advanced hepatocellular carcinoma, and pralsetinib, a RET inhibitor for RET-altered cancers such as non-small cell lung cancer and medullary thyroid carcinoma. It is also pursuing BLU-782, an ALK2 inhibitor in early clinical trials for fibrodysplasia ossificans progressiva. Blueprint Medicines collaborates with partner companies such as Clementia Pharmaceuticals, CStone Pharmaceuticals, Genentech, and Hoffmann-La Roche. Founded in 2008, the company operates in the United States and Europe and combines its Insights-to-Validation platform with a proprietary chemical library to discover and develop new therapeutic compounds and combination therapies in oncology, hematology, and related areas.

ApiJect is a medical technology company that provides a platform for creating scalable prefilled injectors and performing fill-finish of injectable drugs. The platform can operate on its own Blow-Fill-Seal lines or with manufacturing partners, enabling broad adoption of prefilled, single-dose injections. The technology replaces glass, aluminum, rubber, and silicone with medical-grade plastic resin, simplifying the supply chain and reducing environmental impact. By enabling pharma and biotech companies to produce affordable medicines and vaccines, ApiJect helps deliver safe, widely accessible injectable therapies to more patients.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel oral and small-molecule medicines to address rare diseases with significant unmet medical needs. The company's first approved product, RAPIVAB, is an intravenous neuraminidase inhibitor for treating acute uncomplicated influenza, marketed under various names globally. BioCryst has developed ORLADEYO, an oral medication approved for preventing hereditary angioedema attacks in adults and pediatric patients aged 12 and older, and is currently under regulatory review in additional regions. The company is advancing several other product candidates, including BCX9930, an oral Factor D inhibitor for complement-mediated diseases; BCX9250, an ALK-2 inhibitor for fibrodysplasia ossificans progressiva; and Galidesivir, an RNA-dependent RNA polymerase inhibitor aimed at treating various RNA viruses. Founded in 1986 and headquartered in Durham, North Carolina, BioCryst engages in collaborations with various institutions and organizations to enhance its research and development efforts across infectious and inflammatory diseases.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel oral and small-molecule medicines to address rare diseases with significant unmet medical needs. The company's first approved product, RAPIVAB, is an intravenous neuraminidase inhibitor for treating acute uncomplicated influenza, marketed under various names globally. BioCryst has developed ORLADEYO, an oral medication approved for preventing hereditary angioedema attacks in adults and pediatric patients aged 12 and older, and is currently under regulatory review in additional regions. The company is advancing several other product candidates, including BCX9930, an oral Factor D inhibitor for complement-mediated diseases; BCX9250, an ALK-2 inhibitor for fibrodysplasia ossificans progressiva; and Galidesivir, an RNA-dependent RNA polymerase inhibitor aimed at treating various RNA viruses. Founded in 1986 and headquartered in Durham, North Carolina, BioCryst engages in collaborations with various institutions and organizations to enhance its research and development efforts across infectious and inflammatory diseases.

Biohaven Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for neurological diseases and other therapeutic areas. The company focuses on life-changing therapies targeting conditions such as neuromuscular disorders, metabolic diseases, obsessive-compulsive disorder, and various forms of cancer. Its diverse pipeline includes late-stage product candidates that utilize mechanisms such as calcitonin gene-related peptide receptor antagonists, glutamate modulators, and myeloperoxidase inhibitors. Notable candidates in its pipeline include BHV3000-301, BHV3000-302, and BHV3000-303, among others. Biohaven's commitment to addressing unmet medical needs positions it as a significant player in the biopharmaceutical landscape.

Eisai is a global human healthcare company specializing in integrated pharmaceutical businesses focused on oncology and neurology, dementia-related diseases, and neurodegenerative disorders. Established in Japan, Eisai operates globally with a commitment to patient-centric care and innovation.

Epizyme, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to the discovery, development, and commercialization of innovative epigenetic medicines for cancer and other serious diseases. Founded in 2007, the company has developed Tazemetostat, an approved treatment for metastatic or locally advanced epithelioid sarcoma, and is exploring its use in various combinations for other malignancies, including follicular lymphoma, diffuse large B-cell lymphoma, and platinum-resistant solid tumors. In addition to Tazemetostat, Epizyme is advancing other drug candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, and inhibitors targeting PRMT5 and PRMT1 for various solid tumors and blood cancers. The company collaborates with several prominent organizations in the pharmaceutical sector to enhance its research and development efforts.